Release Date: January 10, 2017
Expiration Date: January 10, 2018
Media: Print with online posttest, evaluation, and request for credit
Overview
This activity is designed to inform physicians about the current and emerging treatment landscape in chronic lymphocytic leukemia (CLL) and factors that influence the sequencing of CLL therapies.
Instructions For This Activity & Receiving Credit
|
Target Audience
This activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with hematologic malignancies. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other healthcare providers with an interest in the current topic are also invited to participate.
Learning Objectives
After participating in this CME activity, learners should be better prepared to:
- Identify the factors that guide individualized treatment decision making in patients with newly diagnosed and relapsed/refractory CLL
- Summarize key clinical trial findings demonstrating the safety and efficacy of recently approved CLL therapies
- Utilize evidence-based data to appropriately implement new CLL therapies into clinical practice
- Recognize the advantages and limitations of allogeneic hematopoietic stem cell transplantation in patients with CLL
- Discuss novel agents that are currently under investigation as monotherapy or in combination with other agents in the treatment of patients with CLL
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.
Faculty
Susan M. O’Brien MD
Associate Director for Clinical Science,
Chao Family Comprehensive Cancer Center
Medical Director,
Sue and Ralph Stern Center for Cancer Clinical Trials and Research
UC Irvine Health
Disclosure: Grant/Research Support - Acerta, TG Therapeutics, Regeneron, Gilead, Pharmacylics, ProNAi Consultant - Amgen, Celgene, GSK, Janssen
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Accreditation/Credit Designation
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.
This activity is funded by PER®.
Off-Label Disclosure and Disclaimer
This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
Disclaimer
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®,LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
Phone: (888) 949-0045
E-mail: [email protected]